GlassScriptPhysician profile
Laney T Combs
NPI 1265084693
$5,324.73
in general payments reported to CMS, 2019-2025
47 companies · $1,869 in 2025
The $1,869 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $951 · 2023: $1,063 · 2024: $1,013 · 2025: $1,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,945.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $697.55 | 2021-2025 | |
| Lilly USA, LLC | $547.93 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $526.39 | 2022-2025 | |
| Amgen INC. | $291.31 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $204.65 | 2024-2025 | |
| Glaxosmithkline, LLC. | $200.44 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $191.86 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lundbeck LLC | $182.13 | 2024-2025 | Vyepti |
| Corcept Therapeutics | $169.12 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $168.51 | 2021-2024 | Airsupra |
| Organogenesis INC. | $165.74 | 2021 | |
| Collegium Pharmaceutical, INC. | $162.32 | 2025 | Jornay Pm |
| Ibsa Pharma INC. | $157.08 | 2023-2025 | Tirosint, Licart, Flector |
| Abbott Laboratories | $144.83 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $136.23 | 2023-2025 | Cologuard Collection Kit |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $123.84 | 2023-2025 | Qutenza |
| Antares Pharma, INC. | $110.60 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Teva Pharmaceuticals USA, INC. | $108.23 | 2023-2025 | Ajovy |
| Corium, LLC | $93.38 | 2022-2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.29 | 2021-2023 | Jardiance |
| Organon LLC | $78.59 | 2023 | Nexplanon |
| Janssen Pharmaceuticals, INC | $72.27 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $56.28 | 2025 | Symbravo |
| Noven Therapeutics, LLC | $55.51 | 2025 | Xelstrym, Secuado |
| Astellas Pharma US INC | $53.07 | 2024-2025 | Veozah |
| Mannkind Corporation | $52.39 | 2025 | |
| Smith+Nephew, INC. | $43.78 | 2025 | Grafix, Stravix |
| Neos Therapeutics, LP | $40.42 | 2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $36.50 | 2023 | Quviviq |
| Avion Pharmaceuticals | $34.39 | 2023 | NP Thyroid 60 |
| Grt US Holding, INC. | $32.28 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $29.31 | 2025 | Neffy |
| Nevro Corp. | $28.39 | 2023 | Senza |
| Seqirus USA INC | $23.00 | 2025 | Fluad, Flucelvax |
| Daiichi Sankyo INC. | $22.56 | 2025 | Injectafer |
| Genentech USA, INC. | $22.55 | 2022 | |
| Scynexis, INC. | $18.62 | 2022 | |
| Inspire Medical Systems, INC. | $17.60 | 2025 | Inspire |
| Cequr Corporation | $17.41 | 2025 | Cequr Simplicity |
| Eisai INC. | $16.44 | 2025 | |
| Merck Sharp & Dohme LLC | $16.27 | 2023 | Vaxneuvance, M-M-R II, Vaxelis |
| Supernus Pharmaceuticals, INC. | $16.08 | 2022 | |
| Amarin Pharma, INC. | $15.46 | 2022 | |
| Si-Bone, INC. | $14.84 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.01 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $13.80 | 2022 | |
| Allergan, INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laney Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.